Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir simplification strategies in virologically suppressed adults with HIV
2015-000274-35Phase 4Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dolutegravir and lamivudine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Therapeutic efficacy and virological failure rate. Started Feb 2015; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2015-000274-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000274-35.